South Korea faces a common, but critical, challenge in the world of healthcare: how to make innovative medicines swiftly available while keeping healthcare budgets intact. The country has ventured forth with new strategies, including economic evaluation exemptions and risk-sharing agreements (RSAs), targeting this issue directly. Despite the strategic policy adaptations, the real-world effects of these mechanisms have sparked a keen interest for empirical examination. Leveraging a substantial dataset on recent drug assessments, this study sheds light on how these measures play out in the reality of South Korea’s healthcare system.
Investigative Approach
Researchers embarked on a comprehensive retrospective observational study analyzing 85 new drugs assessed by the Health Insurance Review and Assessment Service (HIRA) from 2022 to 2024. The study methodically categorized the available Health Technology Assessment (HTA) datasets according to evaluation outcomes, pricing ratios, and anticipated budget impacts. Emphasizing statistical rigor, the research employed descriptive analysis alongside correlation testing and multivariable linear regression to uncover significant patterns and predictors influencing drug access.
Emerging Findings
An impressive 82% of the drugs assessed found their way to reimbursement. A complete endorsement from HIRA significantly forecasted successful drug listings. Interestingly, drugs entailing a moderate budget impact, namely 1.5 to 10 billion Korean Won, tended to see swifter market entry. Moreover, international price ratios, which averaged 64% compared to reference countries, stood out as a remarkably consistent predictor across various scenarios.
This study suggests that:
- The speed of drug listing is influenced by the scale of budget impact.
- International price ratio occupies a pivotal role in listing outcomes.
- HIRA’s full recommendation acts as a significant predictor for successful drug listing.
The fundamental role of evaluation outcomes and budgetary projections in drug reimbursement surfaces as a key takeaway from this study. Enhancing HTA processes and the nuanced adoption of RSAs emerge as promising pathways to streamline access to medications without destabilizing fiscal foundations. It becomes evident that strategic refining of these policies can potentially lead to more efficient healthcare delivery. For stakeholders, considering these insights is crucial—policy refinements must balance accessibility with economic prudence, integrating adaptability into systems designed to meet the ever-evolving challenges of healthcare demands. Equipping healthcare providers with better tools for policy implementation and ensuring that financial frameworks can withstand these adjustments will be essential for sustaining progress in the availability of innovative treatments.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
